Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer
Uro-Oncology
Related content
Uro-Oncology
Efficacy and Feasibility of Cabazitaxel for Very Elderly Patients of ≥ 80 Years of Age With Metastatic Castration-Resistant Prostate Cancer: A Real-World Multi-Intuitional Analysis
Prostate
Suzuki K, Hirata J, Okamura Y, Bando Y, Hara T, Terakawa T, Hyodo Y, Chiba K, Teishima J, Miyake H
doi: 10.1002/pros.24889
Uro-Oncology
Bellmunt risk score as a survival predictor in patients with metastatic castration-resistant prostate cancer
Prostate
Büttner T, Klümper N, Weiten R, Lossin P, Latz S, Jacobs C, Ritter M, Hauser S, Ellinger J, Krausewitz P
doi: 10.1002/pros.24747
Uro-Oncology
Outcome of Subsequent Therapies After (177)Lu-Vipivotide Tetraxetan for Metastatic Castrate-Resistant Prostate Cancer: A Tertiary Cancer Center Experience
Prostate
Losee M, Kavanaugh M, Liu M, Borges N, Haberman V, Ritzer J, Wolanski A, Bhimaniya S, Choudhury AD, Hyun H, Stoltenberg H, Kilbridge KL, Morgans A, Pomerantz M, Robertson M, Sakellis C, Shah H, Taplin ME, Wei XX, Ng T, Ravi P, Jacene H
doi: 10.1002/pros.24880
Uro-Oncology
Treatment patterns and oncological outcomes of older adults with metastatic prostate cancer in real-world setting
J Am Geriatr Soc
Wenzel M, Hoeh B, Wagner N, Koll F, Siech C, Humke C, Steuber T, Graefen M, Tilki D, Kluth L, Traumann M, Banek S, Chun FKH, Mandel P
doi: 10.1111/jgs.19045
Further Publications Urology
Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials
Prostate Cancer Prostatic Dis
Shelan M, Achard V, Appiagyei F, Mose L, Zilli T, Fankhauser CD, Zamboglou C, Mohamad O, Aebersold DM, Cathomas R
doi: 10.1038/s41391-024-00829-9
Uro-Oncology
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study
Eur Urol
Saad F, Hussain MHA, Tombal B, Fizazi K, Sternberg CN, Crawford ED, Nordquist LT, Bögemann M, Tutrone R, Shore ND, Belkoff L, Fralich T, Jhaveri J, Srinivasan S, Li R, Verholen F, Kuss I, Smith MR
doi: 10.1016/j.eururo.2024.03.036
COMMENTED
Uro-Oncology
Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK Study
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
Eur Urol
Freedland SJ, Mulhall JP, Gleave M, Giorgi U, Saad F, Rannikko A, Ivanova JI, Nasr AF, Reisman AL, Ganguli A, Kral P, Turnbull J, Shore N
doi: 10.1016/j.eururo.2025.02.006
RECOMMENDED
HPV and Gynecologic Cancer
Overall Survival Following Interval Complete Gross Resection of Advanced Ovarian Cancer via Laparoscopy Versus Open Surgery: An Analysis of the National Cancer Database
★ 2
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
J Clin Med
Hayek J, An A, Wolf J, Lamiman K, Kim M, Knochenhauer H, Goncalves N, Alagkiozidis I
doi: 10.3390/jcm14041164
Further Publications Urology
The 'Prostate Embolisation AS first-line therapY compAred to meDication in treatment naïVe men with prostAte eNlargement, a randomised ControllEd trial' (P-EASY ADVANCE): a randomised controlled trial of prostate embolisation vs medication for BPH
BJU Int
Brown N, Kiosoglous A, Castree S, Firouzmand S, McBean R, Walker DG, Wallace S, Kua B, Gianduzzo T, Esler RC, Campbell P, Schoeman J, Yaxley J
doi: 10.1111/bju.16479